|
Indolium 1 for Advanced Melanoma Treatment
Application
A small molecule compound for the treatment of melanoma.
Key Benefits
Novel small molecule compound for the treatment of resistant melanoma.
Well tolerated in vivo.
Market Summary
Malignant melanoma is a type of skin cancer that begins in melanocyte cells. Melanoma is the 19th most commonly occurring cancer. Exposure to UV radiation...
Published: 1/17/2024
Contributor(s): Jack Arbiser
|
|
Small Molecule Inhibitors for the Treatment of COVID-19 Infection
Application
Small molecule therapy to treat patients infected with COVID-19 virus.
Key Benefits
Current FDA-approved therapeutic can be repurposed to fight COVID-19 infection.
Treatment option for infected COVID-19 patients.
Market Summary
Coronavirus (COVID-19) is an infectious disease that causes severe acute respiratory syndrome coronavirus...
Published: 3/1/2024
Contributor(s): Jack Arbiser, Martijn van Hemert, Melissa Thaler
|
|
Targeted Anti-Cancer Nanoparticle Therapy
Application
A drug-carrying nanoparticle that selectively targets cancer cells.
Key Benefits
Incorporates an already proven anti-cancer therapeutic.
Increases deliverability.
Targets cancer cells.
Market Summary
Tris DBA palladium has been shown to have anti-cancer activity against melanoma and pancreatic cancer. However, Tris DBA has not...
Published: 4/8/2024
Contributor(s): Jack Arbiser, Lily Yang
|
|
Beta Blocker Isomers as Angiogenesis Inhibitors
Application
β-blocker inactive form of propranolol for treatment of angiogenic disease.
Key Benefits
Reduced side-effects, such as low blood pressure and low blood sugar.
Increased anti-angiogenic activity compared to the active isoform.
Market Summary
Angiogenesis is the growth of blood vessels from the existing vasculature. While it...
Published: 1/10/2024
Contributor(s): Jack Arbiser
|
|
Small Molecule NOX Inhibitors of Human Melanoma Cell Proliferation
Application
Triphenylmethane small molecules inhibiting NADPH oxidase (NOX) for the anti-proliferation of melanoma tumor cells.
Key Benefits
Modifies molecular interactions with cellular proteins, reducing cell tumor growth.
Compounds are capable of inhibiting cell proliferation to a greater extent than current competing NOX inhibitors for melanoma...
Published: 7/28/2023
Contributor(s): Jack Arbiser
|
|
DHAA and Derivatives for Treatment of BRAF-V600E-Positive Cancer
Application
Hypolipidemic dehydroacetic acid (DHAA) treatment to prevent growth of BRAF V600E positive tumors.
Key Benefits
Treatment with slows BRAF V600E-positive tumor growth.
Repurposed compound may speed FDA approval.
May be used in combination with other therapies.
Market Summary
Up to 50% of melanoma cases harbor the BRAF V600E mutation,...
Published: 11/27/2023
Contributor(s): Jing Chen, Jack Arbiser, Brian Pollack, Siyuan Xia
|
|
Small Molecule Derivatives of Solenopsin for Cancer Treatment
ApplicationSmall molecule analogs of the naturally-occurring compound solenopsin for the treatment of various cancers including melanoma and angiosarcoma.Key BenefitsAnalogs derived from a naturally-occurring alkaloid. Potential treatment of cancers for which there is a poor prognosis or low survival rate. Market SummaryPhosphoinositol-3 kinase (PI3K)...
Published: 1/25/2024
Contributor(s): Jack Arbiser, J. Phillip Bowen, E. Blake Watkins
|
|
Combination Drug Treatment for Neoplasms Associated with Tuberous Sclerosis
Application
Combination of rapamycin and imatinib for the treatment of neoplasms associated with tuberous sclerosis (TS).
Key Benefits
Combined therapy shows 97% decrease in tumor volume in mouse model of TS compared to vehicle treatment.
Dual therapy blocks two major signaling pathways implicated in TS.
Market Summary
Tuberous sclerosis (TS)...
Published: 9/18/2023
Contributor(s): Jack Arbiser
|
|
Treatment of Dry AMD and Other Ophthalmic Diseases
Application
Fulvene and fulvalene compounds that inhibit nicotinamide adenine dinucleotide phosphate (NADPH) oxidases for the treatment of ophthalmic diseases and disorders including the dry form of age-related macular degeneration.
Key Benefits
Lead compound candidate identified.
Demonstrated positive effects in in vivo preclinical ocular models...
Published: 7/28/2023
Contributor(s): Jack Arbiser
|